Endocrine-Related Cancer
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it
Endocrine-Related Cancer - Tập 20 Số 6 - Trang R341-R356 - 2013
Filamin A (FlnA) has been associated with actin as cytoskeleton regulator.
Recently its role in the cell has come under scrutiny for FlnA's involvement in
cancer development. FlnA was originally revealed as a cancer-promoting protein,
involved in invasion and metastasis. However, recent studies have also found
that under certain conditions, it prevented tumor formation or progression,
confusing th...
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
Endocrine-Related Cancer - Tập 21 Số 5 - Trang 705-714 - 2014
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Endocrine-Related Cancer - Tập 25 Số 3 - Trang 309-322 - 2018
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well
tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS)
experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs
(SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of
telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain,
nau...
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Endocrine-Related Cancer - Tập 22 Số 1 - Trang 1-9 - 2015
Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA)
with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3)
and 5 (SSTR5). Results from preclinical studies indicate that pasireotide can
inhibit neuroendocrine tumor (NET) growth more robustly than octreotidein vitro.
This open-label, phase II study assessed the clinical activity of pasireotide in
t...
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Endocrine-Related Cancer - Tập 23 Số 3 - Trang 191-199 - 2016
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic
pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety
and additional efficacy data from the open-label extension (OLE). Patients with
metastatic grade 1/2 (Ki-67 ≤10%) non-functioning NET and documented baseline
tumour-progression st...
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
Endocrine-Related Cancer - Tập 24 Số 6 - Trang R223-R237 - 2017
The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been
shown to associate with several tissue- and blood-based biomarkers in different
settings. The identification of prognostic factors predicting NEN outcome is of
paramount importance to select the best clinical management for these patients.
Prognostic markers have been intensively investigated, also taking advantage of...
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Endocrine-Related Cancer - Tập 22 Số 4 - Trang 561-575 - 2015
A multianalyte algorithmic assay (MAAA) identifies circulating neuroendocrine
tumor (NET) transcripts (n=51) with a sensitivity/specificity of 98%/97%. We
evaluated whether blood measurements correlated with tumor tissue transcript
analysis. The latter were segregated into gene clusters (GC) that defined
clinical ‘hallmarks’ of neoplasia. A MAAA/cluster integrated algorithm (CIA) was
developed as ...
MicroRNAs associated with small bowel neuroendocrine tumours and their metastases
Endocrine-Related Cancer - Tập 23 Số 9 - Trang 711-726 - 2016
Novel molecular analytes are needed in small bowel neuroendocrine tumours
(SBNETs) to better determine disease aggressiveness and predict treatment
response. In this study, we aimed to profile the global miRNome of SBNETs, and
identify microRNAs (miRNAs) involved in tumour progression for use as potential
biomarkers. Two independent miRNA profiling experiments were performed (n=90),
including prim...
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
Endocrine-Related Cancer - Tập 19 Số 5 - Trang 657-666 - 2012
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog
with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5.
Because of this binding profile, pasireotide may offer symptom control in
patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer
responsive to octreotide LAR. This was a phase II, open-label, multicenter study
of pasi...
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
Endocrine-Related Cancer - Tập 13 Số 4 - Trang 1213-1221 - 2006
About 40% of nonfunctioning pancreatic endocrine carcinomas (NF-PEC) cannot be
cured by surgery due to advanced stage disease. Somatostatin analogues have been
proposed as first line therapy in these cases. We performed a prospective phase
IV study to assess the efficacy of octreotide in advanced NF-PEC and identify
factors predictive of response to therapy. Twenty-one consecutive patients with
oc...
Tổng số: 65
- 1
- 2
- 3
- 4
- 5
- 6
- 7